

Active Research Studies at Corewell Health West

Pediatrics

Neurology

BHV2000-301 (SMA)

Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants with Spinal Muscular Atrophy with Open-Label Extension (RESILIENT)

BHV-3000-312

Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents = 6 to < 18 years of age

BHV-3000-311

Phase 3 randomized, double blind, group sequential, placebo controlled assessing safety & efficacy of rimegepant for treatment of migraine in those aged at least up to less than 18 years of age.

RD2022-0006 Genentech ML 43702

Zogenix CDKL5, ZX008

EFFICACY AND SAFETY OF ZX008 IN SUBJECTS WITH CDKL5 DEFICIENCY DISORDER FOLLOWED BY AN OPEN-LABEL EXTENSION

RD2021-0271 Cerebral Palsy Neurocrine

Phase 3, Randomized, Double-Blind, Placebo controlled assessing efficacy, safety, & tolerability of Valbenazine for treatment of dyskinesia due to CP

Scholar Rock Phase 3

Phase 3 study for Spinal MuscularAtrophy (SMA)

RNS Response

A prospective non-randomized open label single arm pivotal study of RNS System treatment in patients with drug resistant focal onset seizures who are 12 through 17 years of age.

For information about research studies listed please use these contacts below:

Email: researchassist@corewellhealth.org

Phone: 616-391-3050

Lundbeck Migraine

Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of IV eptinezumab in adolescents (12-17 years) for the preventive treatment of chronic migraine

Marinus

An inpatient Phase III Clinical Trial of a Novel Treatment Regimen for Refractory Status Epilepticus

For information about research studies listed please use these contacts below:

Email: researchassist@corewellhealth.org

Phone: 616-391-3050